To ask the Scottish Government, following the treatment, exagamglogene autotemcel, which is a gene-edited therapy manufactured in Scotland, being approved for use in England to treat (a) transfusion dependent thalassaemia and (b) sickle cell disease, what engagement it is having with the NHS and suppliers toward making this available in Scotland, also broken down by what date it will be made available to people eligible for it, if approved.